Which biliary tract cancers benefit from regorafenib–avelumab — and which biomarkers matter?
How mature TLSs identify solid tumor patients more likely to benefit from PD-1 blockade
How plasma LIF predicts immune-checkpoint blockade resistance and a TLS-poor tumor microenvironment
Can CD163 macrophages help select MSS colorectal cancer patients for regorafenib plus avelumab?
Why IDO1 staining can miss L-kynurenine production in colorectal and breast tumors
